Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Multicenter, Open-Label, Safety, and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Next Previous
X
Search
Trial Profile

A Phase 1b/2, Multicenter, Open-Label, Safety, and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orilanolimab (Primary)
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; Proof of concept
  • Sponsors Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 01 Dec 2021 Results assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALXN1830 in patients with pemphigus as well as its effect on disease activity, published in the Journal of Investigative Dermatology.
    • 01 Oct 2019 Status changed from recruiting to discontinued.
    • 21 Aug 2018 Phase has changed from phase 1 to phase 1/2 and a 3 cohort has been added.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top